

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sbpgroup.com](http://www.sbpgroup.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**EXCLUSIVE LICENSE AGREEMENT FOR TQC3721 WITH ASTRAZENECA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Company, has entered into an exclusive license agreement (the “**Agreement**”) with AstraZeneca for the development, manufacturing and commercialization of the Group’s PDE3/4 inhibitor, TQC3721.

Subject to the terms and conditions of the Agreement, the Group shall grant AstraZeneca an exclusive license to develop, manufacture and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future development programmes. The Group is eligible to receive an upfront payment of US 200 million, with additional development, regulatory and sales milestones, totalling up to USD\$1.9 billion, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products. The Agreement is subject to customary closing conditions, including regulatory clearances.

As a global leader in respiratory medicine, this partnership will leverage AstraZeneca’s deep clinical development experience and respiratory expertise with the Group’s innovation capabilities, accelerating the global clinical development of TQC3721, maximizing the potential clinical and commercial value of this potential best-in-class medicine to benefit more patients worldwide.

This partnership represents the Group's second out-licensing transaction with a multinational pharmaceutical company this year, following the licensing collaboration with Sanofi in February. It marks another important milestone in the Group's globalization journey and further validates the Group's in-house innovation capabilities and outstanding business development execution. Looking ahead, the Group will continue to expand its global partner network, deepen diversified strategic collaborations with multinational pharmaceutical companies, and strive to become the preferred innovation partner for global pharmaceutical companies.

### **About TQC3721**

TQC3721 is a highly differentiated inhaled PDE3/4 inhibitor discovered and developed by the Group, with potential best-in-class characteristics across multiple respiratory indications. Through balanced inhibition of both PDE3 and PDE4, TQC3721 is designed to deliver synergistic bronchodilatory and anti-inflammatory effects, with the potential to improve lung function, reduce exacerbations and address broader disease burden in patients with chronic respiratory diseases.

TQC3721 is being developed in China by the Group across nebulized and dry powder inhaler ("DPI") formulations, supporting use across different patient segments, disease severities and commercial settings. In chronic obstructive pulmonary disease ("COPD"), TQC3721 in a nebulized formulation has generated phase IIb data that demonstrate a potential best-in-class profile study<sup>[1]</sup>. The nebulized formulation is currently being evaluated in a Phase III clinical trial in China, while the dry powder inhaler formulation is also being advanced in a Phase II clinical trial. TQC3721 has the potential to become the first domestically developed inhaled dual PDE3/4 inhibitor approved in China.

Source:

[1] Luo Z, et al. TQC3721 in COPD: A Phase 2, Multicentre, Randomised, Double-Blind Trial [Poster]. ERS 2025, Amsterdam, Sept 2025.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 8 July 2026

*As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.*